Ubiquitin drug discovery and diagnostics

The 4th Annual Ubiquitin Drug Discovery & Diagnostics Conference will be held from Monday, July 23rd through Wednesday, July 25th, 2012 at Four Seasons Hotel in Philadelphia, PA, USA.

This premier conference in the ubiquitin field will host an exciting cast of ubiquitin-focused professionals from the academic, pharmaceutical, biotech and business communities.

The three-day conference and workshop is unique in its focus on drug discovery within the ubiquitin pathway, and in its balance of both industry and academic interests. Delegates will have the opportunity to participate in a series of roundtable discussions and poster sessions, and to network with like-minded researchers from around the world.

An innovative pre-conference workshop covering various topics in assays and assay platforms, substrate identification, and ubiquitylation, will begin the program. The focus will be on technical advances in ubiquitin research and its application to the treatment of human disease.

Past Keynote speakers include a Noble Laureate, Distinguished Academic Faculty and C-Suite Executives. The conference program will cover topics in oncology, infectious diseases, neurodegeneration, inflammation, diabetes and muscle wasting.


+ show speakers and program


Kenneth C. Anderson, MD (Keynote Speaker)

Kraft Family Professor of Medicine
Harvard Medical School

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor.

Title: "Targeting Protein Homeostasis in Myeloma"






Keith D. Wilkinson, Ph.D.

Professor of Biochemistry Emory University School of Medicine

Dr. Wilkinson is a world-renowned biochemist and enzymologist, whose laboratory at Emory University has been a pioneer in the development of assays for isopeptidases that work on the ubiquitin family of proteins. He holds a Ph.D. degree from the University of Michigan, and trained as a postdoctoral fellow at the Fox Chase Cancer Center in the laboratory of 2004 Nobel Laureate Dr. Irwin Rose. His discoveries include UCHL1, the first ubiquitin isopeptidase to be described and which is now the target of therapeutic interest.






Alfred Goldberg, Ph.D.

Professor of Cell Biology
Harvard Medical School

Dr. Goldberg is one of the true pioneers of the ubiquitin field, having first described the tagging and degradation of proteins in the 1960s.






William D. Mallender, Ph.D. (Tenative)

Associate Director, Oncology Biochemistry
Millennium: The Takeda Oncology Company

Dr. Mallender is an Associate Director in the Oncology Biochemistry department at Millennium Pharmaceuticals. Prior to working in the Oncology Biochemistry group, Dr. Mallender was a scientist in Millennium’s Lead Discovery group developing HTS and secondary assay protocols for a number of enzyme targets. His research in more recent years has focused on the biochemical study of different enzymes associated with the Ubiquitin Proteasome System. Currently, Dr. Mallender leads several cross functional research teams evaluating Ubiquitin Specific Proteases and Other Deubiquitinating Enzymes as potential targets for drug discovery.”

Title: "Targeting Ubiquitin Isopeptidases"






Karen E. Duff, Ph.D.

Professor of Pathology
Taub Institute at Columbia University/NYSPI

Title: "Interaction between the ubiquitin proteasome system, autophagy and progressive tauopathy in vivo"






Roger A. Greenberg, MD, Ph.D.

Associate Professor, Abramson Family Cancer Research Institute
University of Pennsylvania School of Medicine

Dr. Greenberg acquired his BA at Haverford College, Haverford, PA. Dr. Greenberg studied at Albert Einstein College of Medicine, where he earned his MD, Ph.D. Dr. Greenberg's laboratory, at University of Pennsylvania School of Medicine focuses on mechanisms that are involved in maintaining genome integrity and how this relates to the development and treatment of malignancy. We have a particular interest in understanding how DNA repair mechanisms suppress carcinogenesis in breast and ovarian epithelium.

Title: "Ubiquitin Responses to DNA Double Strand Breaks"






Allan M. Weissman, M.D.

Laboratory Chief
National Cancer Institute

Title: "The ubiquitin-proteasome system and regulation of the mitochondrial fusion machinery: implications for stress-induced apoptosis"






Mark Hochstrasser, Ph.D.

Professor
Yale University

Title: "Ubiquitin-dependent protein quality control at the translocon and its potential disease implications"






Tony Muchamuel, Ph.D.

Senior Scientist
Onyx Pharmaceuticals

Title: "The immunoproteasome as a target in inflammation and autoimmunity"






Ana Maria Cuervo, MD Ph.D. (Tenative)

Professor in the Departments of Developmental and Molecular Biology and of Medicine
Albert Einstein College of Medicine

Title: “Selective autophagy: talking with other proteolytic systems”






Professor Steve Jackson, FRS FMedSci

Head of Cancer Research UK Laboratories
The Gurdon Institute, University of Cambridge
MISSION Therapeutics

Professor Jackson is well known for his pioneering research on how cells respond to DNA damage. In 1997, he founded KuDOS Pharmaceuticals Ltd to develop drugs to interfere with DNA repair so that they kill cancer cells but not normal cells. Based on its successes, particularly in developing the drug olaparib that kills cancer cells by "synthetic-lethality", KuDOS was acquired in 2006 by Astra Zeneca. Recently, Steve co-founded MISSION Therapeutics (Cambridge, UK) to exploit additional drug-discovery and therapeutic opportunities arising from his work on DNA-repair-protein ubiquitylation.

Title: "The DNA-damage response and the Ubiquitin system: new molecular insights and new approaches to cancer therapy"






Rakesh Kumar, Ph.D.

Director, Biology
GlaxoSmithKline

Title: "Opportunities and Challenges of targeting Unfolded Protein Response: A first-in-class inhibitor of PERK"






Chunhai Hao, MD, PhD

Associate Professor
Emory University School of Medicine

Title: "A20 Ubiquitin Pathway and TRAIL Targeted Cancer Therapies"






Mark Rolfe, Ph.D.

President and Chief Scientific Officer
Cleave Biosciences

Dr. Mark Rolfe is an experienced oncology drug discovery and development executive with extensive expertise in small molecule and antibody therapeutics. He has been an invited speaker at numerous international cancer conferences including AACR, ASCO, The Japanese Cancer Association and the EORTC/NCI/AACR Molecular Targets in Cancer Conference. Most recently Mark was CSO of CytomX Therapeutics, a venture backed start-up developing a novel class of protease activated therapeutic antibodies called Probodies.

Title: "Novel Cancer Drug Discovery Targets in the Ubiquitin and Autophagy Systems"






Lawrence R. Dick, Ph.D.

Director of Biochemistry
Millennium: The Takeda Oncology Company

Dr. Larry Dick leads a group of scientists who characterize enzyme and enzyme inhibitor mechanism to find leads for discovering new cancer drugs. His recent research includes work on the investigational drugs MLN9708, a proteasome inhibitor, and MLN4924, an E1-targeted agent, both of which are currently in clinical trials.






J. Steven Jacobsen, Ph.D.

Head of Translational Biology
Proteostasis Therapeutics

Dr. Steve Jacobsen joined Proteostasis in May 2010 after a 22-year career at Pfizer and predecessor companies Wyeth and Lederle. He headed the Alzheimer’s research efforts for 15 years, during which he delivered eight small molecules, vaccines and biologics into development. He is recognized as a pharmaceutical expert in Alzheimer’s disease and is frequently invited to speak at international academic conferences on various discovery, biomarker/translation, and early clinical development programs and has also represented PhRMA (the industry trade group, Pharmaceutical Research and Manufacturers of America) in various meetings on Capitol Hill.

Title: "Small molecule inhibition of Usp14 enhances the proteolytic degradation and clearance of misfolded proteins associated with neurodegenerative diseases"






Dr. Benedikt M. Kessler

Ubiquitin Proteolysis Group Nuffield
Oxford University UK

Dr. Benedikt Kessler is a University Research Lecturer, Group Head / PI, Member of congregation and Grant Holding Senior Scientist at the Henry Wellcome Building for Molecular Physiology, Centre for Cellular and Molecular Physiology with the Ubiquitin Proteolysis Group.

Title: "Targeting the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases"






Craig Leach, Ph.D.

Director, Biology
Progenra, Inc.

Dr Leach received a PhD from the University of Virginia and postdoctoral training at Harvard University in the laboratory of Dr Matthew Michael, where he developed an expertise in cellular mechanisms of ubiquitin family proteins. He currently heads the Assay Development and Drug Metabolism groups at Progenra, Inc., and is active in the generation of novel ubiquitin pathway reagents and other products. He served as a principal organizer of the 2010 Ubiquitin Conference on Drug Discovery and Diagnostics and has been an ad hoc reviewer for the NIH.

Title: "From the top of the mountain: the ten commandments of ubiquitin ligase inhibitor discovery"






Simon S. Wing, MD, FRCPC

Professor
McGill University & McGill University Health Centre Research Institute

Title: "Functions of the USP19 Deubiquitinating Enzyme in Disorders of Muscle Wasting"

23 Jul - 25 Jul 2012

Philadelphia
United States of America
meeting website